Close · Specialty Chemicals

Disclosure Schedules for Specialty Chemicals Independent Sponsors

When the deal is specialty chemicals and the question is Disclosure Schedules, the structure decisions in the first 30 days outlast the next five years. This is where Jason Powell works.

EV range $15M to $200M EV EBITDA $3M to $28M Audience Buy & Sell-side
The deal context

Every specialty chemicals acquisition has its own gravity. Disclosure Schedules is the workstream where independent sponsor counsel earns the seat.

The typical specialty chemicals platform sits at $15M to $200M EV with EBITDA in the $3M to $28M range. The thesis runs on niche formulator or contract manufacturing buy-up. The IP lives in the formulator's head as often as in the company. Structure for that risk explicitly.

The moves

How Disclosure Schedules actually gets structured.

  1. Coordinate disclosure schedule preparation with the seller's diligence file, not against it.

  2. Specifically disclose against specific reps, with cross-reference indexing.

  3. Use the schedules to surface known issues, not to hide them.

  4. Update schedules at signing and again at closing where allowed.

  5. In specialty chemicals, layer in chemical inventory transfer filed as part of the Disclosure Schedules workstream.

The common mistake

Treating disclosure as a dump. The schedules carry the same legal weight as the reps; they need the same precision.

Jason's take
"Disclosure schedules are the most underrated document in M&A. They protect both sides when done right."
Jason Powell · Disclosure Schedules
Capital after close

The deal is one thing. The capital that opens up after close is another.

Most independent sponsors solve the closing capital and then run into the post-close capital problem alone. The capital markets relationships that matter at month 18 are part of this practice.

MONTH 18
Senior refi
MONTH 24
Dividend recap
MONTH 36
Growth equity
YEAR 4–5
Strategic exit
WORK WITH JASON

Bring the specialty chemicals deal. Get Disclosure Schedules done right.

Direct counsel from a securities and M&A attorney with billions in structured transactions, the independent-sponsor-native playbook, and the capital markets network that opens up post-close.